FibroGen (FGEN) Misses Q4 EPS by 79c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to FibroGen (FGEN) Misses Q4 EPS by 79c

FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022 4:01 PM EST

Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular dystrophy Total company revenue increased from $176.3 million in 2020 to $235.3 million in 2021

SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2021 and provided an update on the companys recent developments.

We are excited to advance pamrevlumab in three high... More